Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144170
Status:
COMPLETED
Last Update Posted:
2014-07-02
First Post:
2005-09-02
Brief Title:
TipranavirRitonavir vs Genotypically Defined Protease InhibitorRitonavir in HIV Patients RESIST-2
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Randomized Open-label Comparative Safety and Efficacy Study of Tipranavir Boosted With Low Dose Ritonavir TPVRTV Versus Genotypically-defined Protease InhibitorRitonavir PIRTV in Multiple Antiretroviral Drug-experienced Patients RESIST 2 Randomized Evaluation of Strategic Intervention in Multi-Drug Resistant Patients With Tipranavir
Status:
COMPLETED
Status Verified Date:
2014-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to demonstrate the safety and efficacy of tipranavirritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients Patients must have a viral load 1000 cellsmL and genotype indicating at least one resistance conferring protease inhibitor-mutation as determined from a predefined panel of mutations Any CD4 count is acceptable
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RESIST 2 | None | None | None |